Year: 2025
Type: editorial
Abstract: Multiple sclerosis (MS) is the major neurologic disease of young adults. It is a huge success story for Neurology, with the development of disease modifying therapies (DMTs) for the major relapsing form of the disease. The current understanding of MS involves two distinct central nervous system (CNS) inflammatory neuropathologies [1]. Both are believed to be present in virtually all MS individuals from early on. The first pathology involves focal inflammation, with systemic blood lymphocytes penetrating the CNS to cause contrast enhancing lesions, other macroscopic lesions detected by MRI, and clinical attacks.
Source: Neurotherapeutics
Author: Patricia K. Coyle
Institution: Stony Brook University
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,900
OpenAlex ID: W4412392602